Drug intelligence / Profile preview

MKL003

Development stage: Preclinical
Lead developer: MiHKAL
Modality: Small Molecules

Overview

MKL003 is a preclinical-stage small molecule prodrug being developed by MiHKAL for the treatment of Post-Traumatic Stress Disorder (PTSD). It is designed to be enzymatically activated in human blood, utilizing a methodology similar to lisdexamfetamine (Vyvanse) to achieve tunable release kinetics of an undisclosed active moiety. As of early 2024, the candidate is in the 'Pre-Lead' stage of preclinical development, following the company's validation of its prodrug approach through in vitro digestion assays in human blood.

Beyond the preview

Go deeper on MKL003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MKL003.

Explore the full profile